Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Porter

Showing results (1-10 of 125) with videos related to

Pageof 13
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|December 1, 2006
Deferasirox: An effective once-daily orally active iron chelatorJohn B Porter
Blood Reviews|February 2, 2010
Optimizing iron chelation strategies in beta-thalassaemia majorJohn B Porter
American Journal of Hematology|October 31, 2007
Concepts and goals in the management of transfusional iron overloadJohn B Porter
Annals of the New York Academy of Sciences|August 18, 2010
Deferasirox--current knowledge and future challengesJohn B Porter
Western Journal of Medicine and Surgery|January 11, 2024
Anesthetic Agents in Operations for Gunshot WoundsJohn B Porter
British Journal of Haematology|November 15, 2020
Iron Through the Prism of HaematologyJohn B Porter
Blood Reviews|February 2, 2010
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. IntroductionJohn B Porter
Hemoglobin|December 17, 2009
Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell diseaseJohn B Porter
Hemoglobin|December 17, 2009
Deferasirox: an updateJohn B Porter
Blood Cells, Molecules & Diseases|June 11, 2016
Red blood cell-derived microparticles: An overviewMaxwell Westerman, John B Porter
Pageof 13

Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Drugs of Today (Barcelona, Spain : 1998)|December 1, 2006
Deferasirox: An effective once-daily orally active iron chelatorJohn B Porter
Blood Reviews|February 2, 2010
Optimizing iron chelation strategies in beta-thalassaemia majorJohn B Porter
American Journal of Hematology|October 31, 2007
Concepts and goals in the management of transfusional iron overloadJohn B Porter
Annals of the New York Academy of Sciences|August 18, 2010
Deferasirox--current knowledge and future challengesJohn B Porter
Western Journal of Medicine and Surgery|January 11, 2024
Anesthetic Agents in Operations for Gunshot WoundsJohn B Porter
British Journal of Haematology|November 15, 2020
Iron Through the Prism of HaematologyJohn B Porter
Blood Reviews|February 2, 2010
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. IntroductionJohn B Porter
Hemoglobin|December 17, 2009
Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell diseaseJohn B Porter
Hemoglobin|December 17, 2009
Deferasirox: an updateJohn B Porter
Blood Cells, Molecules & Diseases|June 11, 2016
Red blood cell-derived microparticles: An overviewMaxwell Westerman, John B Porter
Pageof 13